Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma—A Real World Single-Center Analysis

SIMPLE SUMMARY: Adjuvant treatment with the immune checkpoint inhibitors (ICI) pembrolizumab or nivolumab, or the targeted therapies dabrafenib and trametinib is recommended for patients with completely resected stage III melanoma and significantly decreases recurrence risk. Currently, limited data...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffmann, Michèle, Hayoz, Stefanie, Özdemir, Berna C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945449/
https://www.ncbi.nlm.nih.gov/pubmed/35336796
http://dx.doi.org/10.3390/biology11030422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945449/
https://www.ncbi.nlm.nih.gov/pubmed/35336796
http://dx.doi.org/10.3390/biology11030422

Ejemplares similares